Adverse Drug Reactions of Different Brands of Ceftazidime Injection
Information source: National Taiwan University Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infection
Intervention: ceftazidime (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: National Taiwan University Hospital Official(s) and/or principal investigator(s):
Shan-Chwen Chang, MD PhD, Study Chair, Affiliation: National Taiwan University Hospital
Summary
The purpose of this study is to understand whether generic ceftazidime causes different
adverse drug reaction incidence from the brand drug.
Clinical Details
Official title: Adverse Drug Reactions of Different Brands of Ceftazidime Injection
Study design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety Study
Primary outcome: The adverse drug reactions of ceftazidime
Secondary outcome: The effectiveness of ceftazidime
Detailed description:
Ceftazidime is a third generation cephalosporins that should be reserved for severe bacterial
infections. Substitution of the brand ceftazidime with a generic ceftazidime raised some
concerns.
The purpose of this study is to understand whether generic ceftazidime causes different
adverse drug reaction incidence from the brand drug.
Eligibility
Minimum age: 1 Year.
Maximum age: 95 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients in surgical intensive care unit who require ceftazidime treatment
Exclusion Criteria:
- less than 1 year old
Locations and Contacts
National Taiwan University Hospital, Taipei 100, Taiwan
Additional Information
Starting date: March 2001
Ending date: April 2002
Last updated: September 13, 2005
|
